Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06262594 · ClinicalTrials.gov registry record · Phase 3
Lemborexant Treatment of Insomnia Linked to Epilepsy
A Phase 3 study of Epilepsy and Sleep, sponsored by University of Manitoba.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
- 2
- Study locations
NCT06262594: Recruiting Phase 3 study of Epilepsy and Sleep, sponsored by University of Manitoba.
NCT06262594 is a Phase 3 study of Epilepsy and Sleep that is actively recruiting participants, run by University of Manitoba. The registered enrollment target is 26 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06262594, a Phase 3 study of Epilepsy and Sleep, is actively recruiting participants, sponsored by University of Manitoba.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to assess whether Lemborexant can improve sleep in patients with epilepsy.
Primary Outcome
Wake After Sleep Onset (recorded using PSG)
Interventions
- DRUG Placebo
- DRUG Lemborexant
Study Locations (2)
North Carolina
- Duke University - Durham
Manitoba
- Health Sciences Centre - Winnipeg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2024-10-29 |
| Est. Completion | 2027-04-18 |
| Phase | Phase 3 |
What NCT06262594 shows while recruiting
NCT06262594 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06262594 reports a single indexed study location in North Carolina, Manitoba.
Frequently Asked Questions
What is clinical trial NCT06262594 about?
NCT06262594 is a clinical study titled "Lemborexant Treatment of Insomnia Linked to Epilepsy". The goal of this clinical trial is to assess whether Lemborexant can improve sleep in patients with epilepsy.
What is the current status of trial NCT06262594?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2024-10-29. Estimated completion is 2027-04-18.
What conditions does trial NCT06262594 study?
This clinical trial studies the following conditions: Epilepsy, Sleep.
What interventions are being tested in trial NCT06262594?
The interventions under investigation include: Placebo (DRUG), Lemborexant (DRUG).
Who is sponsoring clinical trial NCT06262594?
This trial is sponsored by University of Manitoba, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06262594 being conducted?
This trial has 2 study locations across North Carolina, Manitoba. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06262594's enrollment target sits among peer trials
26 122nd of 160 higher than 39 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
RECRUITING · Phase 3
-
RNS System NAUTILUS Study
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
COMPLETED · Phase 3
-
Clobazam in Patients With Lennox-Gastaut Syndrome
COMPLETED · Phase 3
-
Pediatric Epilepsy Study
COMPLETED · Phase 3
-
IV Lacosamide: The Safety of Intravenous Lacosamide
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI